Background: Leiomyosarcoma (LMS) is one of most aggressive mesenchymal malignancies that differentiate towards smooth muscle. The clinical outcome of LMS patients is poor; as such, there is an urgent need for novel therapeutic approaches. Experimental models such as patient-derived cell lines are invaluable tools for pre-clinical studies. In the present study, we established a stable cell line from the tumor tissue of a patient with a primary LMS of the bone. Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which are primary to the bone. Methods: Bone primary LMS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to pazopanib was evaluated. Results: NCC-LMS1-C1 cells were maintained for over 100 passages. The cells exhibited a spindle shape and aggressive growth; they also expressed smooth muscle actin, reflecting the original LMS tissue (i.e. smooth muscle cells). The cells also showed tumor characteristics such as colony formation on soft agar and sensitivity to pazopanib, doxorubicin and cisplatin, with half-maximal inhibitory concentrations of 4.5, 0.11 and 20 μM, respectively. Proteomic analyses by mass spectrometry and antibody array revealed some differences in the protein expression profiles of these cells as compared to the original tumor tissue. Conclusions: Our results indicate that the NCC-LMS1-C1 cell lines will be useful for LMS research.
Introduction
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy that differentiates towards smooth muscle cells (1) . The vast majority of LMS occurs in the uterus, but extrauterine cases also exist, most commonly involving the retroperitoneum and different parts of the abdominal cavity often in association with large blood vessels (e.g. inferior vena cava). In contrast, primary LMS of the bone is very rare, accounting for less than 1% of all bone sarcomas (2) . Primary LMS of the bone was first described in 1965 (3) , and around 90 cases have been reported, with the largest series being published in 1997 (4) . Due to its rarity, primary LMS of the bone has seldom been the subject of in-depth investigation. Treatment options for LMS vary depending on the location, stage and grade of the primary tumor and the status of metastasis. Surgical resection is the only curative treatment for LMS but patient prognosis is still dismal, especially for late-stage disease. The development of targeted drug treatments has given rise to the possibility of improving the clinical outcome of soft tissue sarcomas including LMS (5, 6) . However, for these to be effective, the molecular mechanisms underlying LMS progression must be clarified.
Cultured cells derived from patient tissue are invaluable tools for studying the molecular backgrounds of malignant phenotypes, examining the roles of specific molecules, and investigating the mode of action of anti-cancer drugs. It was recently reported that some cancer cell lines exhibit genetic traits of the original malignancies, suggesting the utility of cell lines for research purposes (7) . Despite the urgent need for novel therapeutic strategies in LMS, there are only a few LMS cell lines available in public cell banks, none of which were primary to the bone (8) . Establishing additional LMS cell lines can thus facilitate the development of novel drugs for treatment of this disease.
In this study, we established a stable cell line from the tumor tissue of an LMS patient and examined its morphological and functional characteristics, protein expression profile and response to anti-cancer drugs.
Materials and methods
We established a cell line from the metastatic tumor tissue of a patient with primary LMS of the bone and characterized its phenotype and proteome. The study protocol was approved by the Ethics Committee of National Cancer Center, and written informed consent was obtained from all patients.
Case report
The cell line was derived from a metastatic rib tumor from a 42-year-old female patient who was originally diagnosed with leiomyosarcoma of the right femur ( Fig. 1A and B) . No other lesions were detected at initial assessment, and it origin in bone was confirmed by clinical and radiological means. The patient was treated by surgery (wide resection and prosthetic replacement) and pre-/postoperative chemotherapy with doxorubicin, ifosfamide and cisplatin. One year and 9 months later, a lesion was found in the patient's left 10th rib (Fig. 1C and D) . Excisional biopsy was performed and the histology was identical to that of the primary femoral tumor. Based on these findings, the patient was diagnosed with metastatic leiomyosarcoma of the bone. The tumor rapidly spread to lungs, liver and bones. The patient received radio-and chemotherapy with gemcitabine and docetaxel, and is alive with the disease 2 years after development of metastasis.
Histological analysis of tumor tissue
Formalin-fixed, paraffin-embedded tumor tissue was stained with hematoxylin and eosin (H&E) for histological analysis. Sections (4 μm) from representative tissue blocks were treated with 3% hydrogen peroxide to block endogenous peroxidase activity and subjected to heat-induced epitope retrieval. Primary antibodies against smooth muscle actin SMA (1A4, 1:100), cytokeratin (AE1/AE3, 1:100), S100 (polyclonal, 1:2000), desmin (D33, 1:100), myogenin (F5D, 1:100), and caldesmon (h-CD, 1:100) (all from Dako, Glostrup, Denmark) were used for immunohistochemistry. Immunoreactions were detected using the EnVision system (Dako). Diaminobenzidine was used as the chromogen and hematoxylin as a counterstain. Cell morphology was visualized with a phase-contrast inverted microscope (BZ-X710; Keyence, Osaka, Japan).
Establishment of the stable LMS cell line
Tumor cells were obtained from surgically resected tissue. Cells were minced with scissors and seeded in a 24-well tissue culture plate (Thermo Fisher Scientific, Waltham, MA, USA) and cultured in Roswell Park Memorial Institute-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 5% or 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA), 100 U penicillin G and 100 μg/ml streptomycin (Gibco) at 37°C in a humidified atmosphere of 5% CO 2 . The culture medium was changed once or twice a week. When cells reached sub-confluence, they were dispersed with 0.1% trypsin-EDTA (Gibco) and seeded in a new, six-well tissue culture plate. At the next passage, cells were seeded in a 10-cm culture plate and maintained in Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher Scientific, San Jose, CA) with 10% FBS and penicillin/streptomycin (Gibco) for over 30 months and 100 passages.
Immunohistochemical analysis of LMS cells
LMS cells were detached by treatment with trypsin, and cell suspensions were solidified using iPGell (Genostaff, Tokyo, Japan) according to the manufacturer's instructions. Cell masses were fixed with 10% formalin and embedded in paraffin. Cell blocks were cut into sections that were processed for immunolabeling and H&E staining. Sections were incubated with antibodies against the following proteins: SMA (1A4, 1:100), cytokeratin (AE1/AE3, 1:100), S100 (polyclonal, 1:2000), desmin (D33, 1:100), myogenin (F5D, 1:100), and caldesmon (h-CD, 1:100) (all from Dako). Immunoreactivity was detected with enzyme-labeled antibody using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA).
Authentication and quality control of established cell line
Genomic DNA was extracted from excised tissue or cultured cells with DNeasy Blood and Tissue (Qiagen, Valencia, CA, USA) and the AllPrep DNA/RNA mini kit (Qiagen), respectively. The concentration of extracted DNA was determined using a NanoDrop 8000 instrument (Thermo Fisher Scientific), and samples were stored at −20°C until use.
To authenticate the established cell line, the presence of short tandem repeats (STRs) was examined using amelogenin and the STR multiplex assay GenePrint 10 (Promega, Madison, WI, USA) according to the manufacturer's instructions. DNA samples were subjected to PCR amplification of specific regions of the genome, and amplification products were separated on an ABI 3130 or 3500xL Genetic Analyzer (Applied Biosystems, Waltham, MA, USA). Data were processed and evaluated using GeneMapper 5.0 or PeakScanner software (both from Applied Biosystems). STR profiles were compared with those from the American Type Culture Collection (Manassas, VA, USA), German Collection of Microorganisms and Cell Culture (Braunschweig, Germany), or Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) databases.
Mycoplasma contamination of the cell line was also assessed. Cellular DNA was extracted and heated at 95°C for 10 min, and the mycoplasma DNA sequence was amplified with an e-Myco Mycoplasma PCR Detection kit (Intron Biotechnology, Gyeonggido, Korea) and visualized by agarose gel electrophoresis.
Cells in logarithmic phase were incubated overnight in culture medium containing colcemid (10 ng/ml; Nacalai Tesque, Kyoto, Japan), then resuspended in a hypotonic solution (0.075 mol/l KCl: 0.8% sodium citrate = 1:1) and fixed in a 3:1 solution of methanol and glacial acetic acid. Chromosomes were processed by Giemsa staining and the number of cells in M phase was counted under the microscope (Carl Zeiss, Jena, Germany).
Functional characterization of established cell line
The growth characteristics of the cell line were analyzed as follows. Cells were seeded in triplicate in 96-well culture plates at 4, 8 or 12 × 10 3 cells/well. Over the next 1-5 days, tumor cell proliferation was evaluated using Cell Counting Kit (CCK)-8 kit (Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufacturer's protocol. Briefly, CCK-8 reagent was added to each well followed by incubation at 37°C for 2 h. The absorbance at 450 nm was measured with a microplate reader (Bio-Rad, Hercules, CA, USA) and plotted as a function of days after cell seeding.
The capacity for anchorage-independent colony formation was also assessed. The bottom of a 35-mm dish was coated with 0.5% low melting agarose (Noble agar; Sigma-Aldrich) along with DMEM supplemented with 10% FBS and penicillin/streptomycin, and then covered with 0.33% agarose containing 5 × 10 4 cells. The plates were incubated at 37°C and 5% CO 2 for 4 weeks, and colonies containing >50 cells were identified under a Primo Vert inverted microscope (Keyence). The assay was performed in duplicate. 
Invasion assay

Proteomic analysis
Proteins were extracted from frozen tissue and cultured cells using urea lysis buffer (6 M urea, 2 M thiourea, 10% TritonX-100 and 3% CHAPS) (9) or protein lysis buffer included in the Signal Explorer Antibody Microarray kit (Full Moon BioSystems, Sunnyvale, CA, USA). Protein concentration was measured using a protein assay kit (Bio-Rad). Protein samples analyzed by mass spectrometry (MS) were first digested with trypsin by filter-aided sample preparation (FASP Protein Digestion kit; Expedon, Cambridge, UK) (10) according to the manufacturer's instructions. Briefly, 25 μg of protein were reduced and alkylated and then spin filtered, washed several times and treated overnight at 37°C with sequencing grade modified trypsin (Promega). The proteins were eluted from the column and concentrated by vacuum centrifugation (Thermo Fisher Scientific), then solubilized with formic acid and subjected to liquid chromatography coupled with tandem MS on a LTQ-Orbitrap XL instrument (Thermo Fisher Scientific). Acquired mass and tandem mass spectra were used for peptide identification using the SWISS-PROT database (Homo sapiens, 20 205 sequences in the Swiss Prot_2015_09.fasta file) and Mascot v.2.5.1 software (Matrix Science, London, UK). The search parameters were as follows: tolerance of one missed trypsin cleavage; variable modifications on the methionine (oxidation, +16 Da), serine, threonine and tyrosine (phosphorylation, +80 Da) residues; fixed modification on the cysteine residue (carbamidomethyl, +57 Da); maximum precursor ion mass tolerance of ±10 ppm; and fragment ion mass tolerance of ±0.8 Da. An abnormal chromosome number was observed in the cell line. Total chromosome number was determined based on chromosome counts in 20 cells. Proteins (50 μg) extracted from tumor tissue or the established LMS cell line with protein lysis buffer included in the Signal Explorer Antibody Microarray kit were labeled with biotin and applied to an antibody microarray pre-treated with blocking solution. Immune complexes formed on the 3-D polymer-coated glass slide were detected with Cy3-labeled streptavidin (1:1000 dilution; GE Healthcare Biosciences, Uppsala, Sweden). After incubation for 20 min, the slides were washed and completely dried, then scanned with a laser scanner (Typhoon Trio; GE Healthcare Biosciences). Data were quantified with ImageJ software (National Institutes of Health, Bethesda, MD, USA). Proteins with an intensity value >0.3 were used for further analyses (11) .
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations were inferred using Database for Annotation, Visualization and Integration Discovery software (http://david.abcc. ncifcrf.gov/) (12) . KEGG analysis results were plotted using the 'treemap' module of R software (13) .
Results and discussion
Morphological characterization of LMS cell line
Original tumor tissue was morphologically characterized by a certified pathologist (A.Y.). The tissue exhibited the typical features of high-grade LMS, including intersecting fascicles of pleomorphic spindle-shaped cells with eosinophilic cytoplasm ( Fig. 2A and B) , and diffusely positive immunoreactivity for SMA (Fig. 2C ) and hcaldesmon (Fig. 2D) . AE1/AE3, desmin and myogenin expression was absent, and S100 signals were rare and weak. The NCC-LMS1-C1 LMS cell line was derived from the tumor tissue. Cells were resuspended and embedded in agarose for morphological observation (Fig. 2E) , and consecutive sections were analyzed by immunocytochemistry (Fig. 2F-K) . NCC-LMS1-C1 cells were positive for SMA (Fig. 2F) and negative for the other biomarkers examined (Fig. 2G-K) . These results suggest that the LMS cell line loses some molecular features relative to the original tumor tissue.
Authentication of NCC-LMS1-C1 cells
We examined the status of STRs in the original tumor tissue and NCC-LMS1-C1 cells. Of the 10 STRs, three showed non-identical patterns, indicating possible loss of heterozygosity (Supplementary Table 1 ). We therefore concluded that NCC-LMS1-C1 cells are derived from the LMS tumor tissue. A database search confirmed that the cells did not originate from contamination by cultured cells from human tissue and indicated that NCC-LMS1-C1 cells are a novel cell line.
We investigated the presence of mycoplasma DNA in NCC-LMS1-C1 cells by PCR and found no evidence of contamination (data not shown). A chromosome analysis revealed an average of 65 chromosomes among 20 cells (Table 1) , consistent with the observation that LMS is a sarcoma with a complex karyotype (14) .
Phenotypic characterization
NCC-LMS1-C1 cells exhibited a spindle shape (Fig. 3A) , consistent with the morphology of cells in the original tumor tissue. NCC-LMS1-C1 cells showed constant growth when different numbers were seeded (Fig. 3B) , indicating that these cells would be useful in experiments those require data on cell growth. When seeded on a soft agar plate, the cells formed colonies (Fig. 3C) , highlighting their potential for tumorigenicity.
The response of NCC-LMS1-C1 cells to treatment with anticancer drugs such as pazopanib, doxorubicin and cisplatin was examined; the half-maximal inhibitory concentrations were 4.5, 0.11 and 20 μM, respectively (Fig. 3D) . Pazopanib is effective against soft tissue sarcomas including LMS (15) . Pazopanib is a pan-kinase inhibitor; the mechanisms underlying inherent or acquired resistance to pazopanib are not fully understood. Patientderived cancer models will be a useful resource for such antineoplastic agents.
We evaluated the invasive capacity of NCC-LMS-C1 cells with the transwell invasion assay. At both cell densities (1 × 10 5 or 2 × 10 5 cells), cell invasion increased in a time-dependent manner ( Fig. 4A and B) . These results indicate that NCC-LMS1-C1 cells have invasive potential.
Proteomic profiling of LMS tumor tissue and cell line
MS-and antibody-based proteomic analyses were carried out to investigate differences between LMS tumor tissue and NCC-LMS1-C1 cells. The two approaches provided information on different aspects of the proteome. A total of 1562 and 1682 proteins were identified in tumor tissue and NCC-LMS1-C1 cells, respectively, by MS; of these, 786 and 906 were observed only in tumor tissue and NCC-LMS1-C1 cells, respectively. The functional classification of identified proteins is illustrated as a tree map based on Kyoto Encyclopedia of Genes and Genomes pathway analysis (Fig. 5) . In tumor tissue, most enriched proteins had the following functions 'Focal adhesion', 'Biosynthesis of antibiotics', and 'Carbon metabolism' (Fig. 5A) , whereas in NCC-LMS1-C1 cells, the predominant functions were 'Ribosome', 'Proteasome' and 'Spliceosome' (Fig. 5B) . 'Focal adhesion', 'ECM-receptor interaction' and 'Complement and coagulation cascades' pathways were only detected in tumor tissue (Fig. 5C ). 'Ribosome', 'Spliceosome' and 'Proteasome' were specific to the established cell line (Fig. 5D) , whereas 'Protein processing in endoplasmic reticulum', 'Biosynthesis of antibiotics' and 'Carbon metabolism' were enriched in all cell lines (Fig. 5E ). The proteins in these pathways may be associated with pathways close to the tumor and are worth investigating in NCC-LMS1-C1 cells. Protein assignments for the individual functional categories are summarized in Supplementary Table 2 . These results suggest that certain molecular functions were lost during establishment of the cell line in accordance with our immunohistochemical findings (Fig. 2) . Protein expression profiles of the original tumor tissue and NCC-LMS1-C1 cells were also examined with an array of antibodies against 1324 proteins. We imposed a strict criterion such that only proteins with high expression were selected; ultimately, data for 185 proteins were analyzed (Supplementary Table 3 ). Consistent with the MS data, about half of the proteins (98/185) were differentially expressed between the original tumor and NCC-LMS1-C1 cells (fold difference > 2); 87 showed differences in intensity that were ≤2-fold. The tree map indicated that most of the 185 proteins belonged to 14 pathways (Fig. 6A) . The 87 proteins showed intensity differences ≤2-fold and were assigned to six pathways (Fig. 6B ) that were conserved between the original tumor and NCC-LMS1-C1 cells, including 'Pathways in cancer', 'Colorectal cancer', 'Leukocyte transendothelial migration', 'Prostate cancer', 'Prion diseases', and 'Amyotrophic lateral sclerosis'. These proteins are worth investigating using NCC-LMS1-C2 cells (Supplementary Table 4 ). The 98 proteins differentially expressed between the original tumor tissue and NCC-LMS1-C1 cells were grouped into four categories (Fig. 6C) , and had the following functions: 'Leukocyte transendothelial migration', 'Amyotrophic lateral sclerosis', 'Prostate cancer', 'Focal adhesion', 'Cell adhesion' and 'Neurotrophin signaling pathway'. The proteome also included proteins related to 'Tight junction', 'Apoptosis', 'Helicobacter pylori infection', 'Pancreatic cancer' and 'Colorectal cancer'. Proteins that were most highly expressed in tumor tissue and NCC-LMS2-C1 cells included those associated with 'Prion diseases', 'Colorectal cancer' and 'Pathways in cancer'. Proteins unique to NCC-LMS1-C1 cells included those involved in 'NOD-like receptor signaling pathway', 'Leukocyte transendothelial migration', 'Epithelial cell signaling in Helicobacter pylori infection' and 'Prostate cancer'. The detailed results are summarized in Supplementary Table 4 .
The high failure rate in clinical trials can be attributed to the discrepancy between pre-clinical model systems and tumor cells in living tissue. Patient-derived cell lines maintained in cultures for relatively short periods of time can potentially overcome such discrepancies. However, our results suggest that proteome contents changed during the process of cell line establishment. This is consistent with a previous report that even short-term culture induces changes in protein expression in bladder cancer cells (16) . The alterations could be due to clonal expansion of specific cell populations in the tumor tissue, response to environmental changes, or genetic and/or epigenetic alterations during cell line establishment. Although cancer cell lines derived from patients are in many ways more useful than those that are commercially available, our data highlight their limitations. Further studies of proteomic alterations in tumor-derived cell lines are required to evaluate the functional consequences of such changes. Moreover, LMS cell lines originating from different organs have distinct characteristics; this should be taken into consideration during the establishment of multiple LMS cell lines derived from bone.
Conclusions
Primary LMS of the bone is rare and for this reason has not been investigated in great detail. The NCC-LMS1-C1 cell line established here can serve as a useful experimental model for studying the molecular mechanisms underlying the development of primary LMS of the bone.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online. Figure 6 . Tree map view of KEGG pathway categories for proteins identified by antibody array. KEGG pathway categories for proteins highly expressed in both tumor tissue and NCC-LMS1-C1 cells. The color and size of individual areas correspond to the degree of enrichment and number of proteins assigned to the category, respectively. P < 0.05 was considered statistically significant.
